Users of OTC derivatives are not prepared for regulatory onslaught

Margie Lindsay
26 Jan 2011

Tweet
Facebook
LinkedIn
Save this article
Send to
Print this page

Regulatory requirements expected in the US and Europe will be difficult for buy-side companies to implement. Counterparty credit risk and collateral management for OTC derivatives will be challenging.

The analysis* by BNY Mellon shows what the buy-side needs to do now as well as when expected industry regulatory changes are made. The study focused on the standardisation of over the counter (OTC) derivatives and a migration to central clearing.

Until now industry best practice in this area has

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to print this content. Please contact [email protected] to find out more.

You are currently unable to copy this content. Please contact [email protected] to find out more.

You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email [email protected]t

You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email [email protected]